Search - tctmd.com

Displaying 21 - 40 of 44

Sort: Relevancy | Date

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

Presentation ESC 2023

The HEART-FID Trial: Efficacy and Safety of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency

Presenter: Robert Mentz

August 28, 2023

Presentation ESC 2023

DICTATE AHF: Efficacy and Safety of Dapagliflozin in Acute Heart Failure

Presenter: Zachary Cox

August 28, 2023

Presentation ESC 2023

The Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial

Presenter: Jozine M. ter Maaten

August 28, 2023

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

News Conference News ESC 2023

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

Shelley Wood

August 26, 2023

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Shelley Wood

August 25, 2023

Presentation ESC 2022

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Presenter: Otavio Berwanger

August 29, 2022

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Todd Neale

August 27, 2022

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

L.A. McKeown

August 27, 2022

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

News Conference News ESC 2022

No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE

Shelley Wood

August 26, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

Todd Neale

August 27, 2021

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

Advertisement

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

The HEART-FID Trial: Efficacy and Safety of Ferric Carboxymaltose as Treatment for Heart Failure with Iron Deficiency

DICTATE AHF: Efficacy and Safety of Dapagliflozin in Acute Heart Failure

The Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE

What’s Going to Be Hot at ESC 2022?

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content